Neuroendocrine Neoplasms (NENs): Classification, Pathology, Grading, IHC, Molecular Alterations, and Prognosis

1. Definition and Origin

• Goldman-Cecil Medicine, p. 2754

2. WHO Classification of NENs (2022, 5th Edition)

2.1 Top-Level Division: Differentiation

This distinction is fundamental because NETs and NECs have different molecular pathogeneses, respond to different therapies, and have radically different prognoses. A high-grade NEC is NOT simply a "high-grade NET."

• Henry's Clinical Diagnosis and Management by Laboratory Methods, p. 425
• Fischer's Mastery of Surgery, p. 5113

2.2 WHO Grading System for Well-Differentiated NETs

• Small Cell NEC (SC-NEC) - analogous to SCLC
• Large Cell NEC (LC-NEC)

An important distinction: ~10% of well-differentiated NETs can have Ki-67 > 20% ("G3 NET") with relatively better outcomes than poorly differentiated NECs with the same Ki-67. This distinction is made on morphology and confirmed by molecular markers.

• Sabiston Textbook of Surgery, p. 1591 (Table 76.2)
• Yamada's Textbook of Gastroenterology, p. 511

3. Pathology of NETs

3.1 Gross Pathology

3.2 Histopathology of Well-Differentiated NETs

• Uniform, small to medium-sized cells growing in organoid patterns: nests, trabeculae (ribbons), or gyriform (pseudoglandular) arrangements
• Cells have eosinophilic, finely granular cytoplasm (reflecting abundant neurosecretory granules)
• Round to oval nuclei with "salt and pepper" chromatin (finely stippled) - the hallmark of neuroendocrine differentiation
• Nucleoli are absent or inconspicuous
• Mitotic figures are rare; necrosis is absent in low-grade tumors

3.3 Histopathology of Poorly Differentiated NECs

• Small cell NEC: sheets of densely packed small cells (< 3 lymphocyte diameters, ~20 µm), scant cytoplasm, poorly defined cell borders, granular "salt and pepper" chromatin, absent/inconspicuous nucleoli, frequent nuclear molding, extensive necrosis, and very high mitotic rate (~60 mitoses per 2 mm²). Appears blue on H&E at low power due to high N:C ratio.
• Large cell NEC: nests of cells with moderate-to-abundant cytoplasm, large vesicular nuclei with prominent nucleoli, frequent necrosis, and high mitotic count (must be ≥ 11 per 2 mm² to distinguish from low-grade carcinoids).
• Fishman's Pulmonary Diseases & Disorders, p. 3618-3623

4. Immunohistochemistry (IHC) of NETs

4.1 Pan-Neuroendocrine Markers

4.2 Proliferative Marker

• Ki-67 (MIB-1 clone): The single most important prognostic IHC marker. Nuclear brown staining quantified as the % of positive neoplastic nuclei. The foundation of the WHO grading system. Ki-67 > 20% with poorly differentiated morphology defines NEC (G3).

4.3 Site-Specific and Lineage-Specific IHC Markers

Critical note: Functionality is defined by the presence of clinical symptoms, not IHC staining alone. Nonfunctional NETs frequently stain for multiple hormones but fail to secrete them at symptom-causing levels.

• Yamada's Textbook of Gastroenterology, p. 539-551; Fischer's Mastery of Surgery, p. 4237-4246

5. Molecular Alterations

5.1 Pancreatic NETs (pNETs) - Molecular Profile

• Inactivating mutations in 44% of sporadic pNETs
• MEN1 encodes menin, a scaffold protein in a histone methyltransferase complex (chromatin remodelling)
• Also the germline mutation causing MEN1 syndrome (multiple endocrine neoplasia type 1: parathyroid hyperplasia, pituitary tumours, pNETs)

• Inactivating mutations in DAXX (death domain-associated protein) or ATRX (α-thalassaemia/intellectual disability syndrome X-linked chromatin remodeller) in 43% of pNETs
• DAXX and ATRX form a chromatin remodelling complex involved in telomere maintenance
• pNETs with DAXX or ATRX mutations show Alternative Lengthening of Telomeres (ALT) - a telomerase-independent mechanism of telomere maintenance
• Nearly half of pNETs have a somatic mutation in DAXX or ATRX (but not both), consistent with their function in the same pathway
• DAXX/ATRX loss is an independent adverse prognostic marker: 5-year survival ~45% in ALT-positive vs ~85-86% in ALT-negative/DAXX/ATRX-intact tumours
• Routine IHC for DAXX/ATRX loss (loss of nuclear staining) and ALT assessment are now recommended in practice

• Loss-of-function mutations in PTEN and TSC2 tumour suppressors in ~14% of pNETs
• Results in oncogenic activation of the mTOR signalling pathway
• This is the therapeutic target for everolimus (mTOR inhibitor), an approved treatment for advanced pNETs
• Loss of PTEN protein (with increased pAKT expression) may further identify more aggressive GI NETs

• Allelic losses at 1p, 1q, 3p, 11p (MEN1 locus), and 22p
• Robbins, Cotran & Kumar Pathologic Basis of Disease, p. 2353-2359; Goldman-Cecil Medicine, p. 2793-2795

5.2 GI (Midgut/Carcinoid) NETs - Molecular Profile

• Chromosomal losses at 18q, 18p, 9p, and 16q are characteristic
• Small intestinal NETs have a low overall mutation rate (one of the lowest of any cancer)
• Recurrent somatic mutations in CDKN1B (encoding the cell cycle inhibitor p27) in ~8% of tumours
• Epigenetic dysregulation (e.g., promoter methylation, histone modification) plays an emerging role

5.3 Neuroendocrine Carcinomas (NECs) - Molecular Profile (Distinctly Different)

• NECs resemble high-grade carcinomas molecularly and share features with SCLC
• TP53 mutations - hallmark of NEC
• RB1 inactivation - common in SCLC and large cell NEC
• Loss of both TP53 and RB1 is characteristic of small cell NEC
• These mutations are rare in well-differentiated G3 NETs, which is a key distinguishing feature

5.4 Hereditary Syndromes Associated with NENs

• Goldman-Cecil Medicine, p. 2805

6. Clinical Examples of NETs

6.1 Insulinoma (Pancreatic β-cell NET)

• Most common functional pNET (incidence: 1-4 per million/year)
• Nearly 90% are benign (G1), solitary, < 2 cm
• Whipple's triad: hypoglycaemic symptoms + blood glucose < 50 mg/dL + relief with glucose
• IHC: positive for insulin, synaptophysin, chromogranin A
• Morphology: well-differentiated, trabecular/nesting pattern; amyloid deposits in stroma (unique)
• Molecular: sporadic insulinomas rarely carry MEN1 mutations; mostly carry YY1 and EIF1AX mutations

6.2 Gastrinoma (Zollinger-Ellison Syndrome)

• 60-90% are malignant (nodal and liver metastases)
• 80-100% located in the duodenum (small, < 1 cm); 20% pancreatic (larger)
• 20-25% occur in MEN1 context (MEN1/ZES): 80-95% are duodenal in this setting
• Gastrin excess drives parietal cell hyperplasia → elevated basal acid output → peptic ulcers, diarrhea, steatorrhoea
• Diagnosis: elevated fasting gastrin (> 1000 pg/mL diagnostic; secretin stimulation test for borderline)

6.3 Small Bowel (Midgut) NET / "Carcinoid"

• Arise from enterochromaffin (Kulchitsky) cells in crypts of Lieberkühn
• Most common small bowel malignancy (>20% of malignant small bowel tumours)
• Located within 60 cm of the ileocecal valve (35-45% of all GI NETs)
• At presentation: 40% have multifocal tumours > 2 cm; 70% invade muscularis propria/lymph nodes; 50% have liver metastases
• Carcinoid syndrome (occurs only with liver metastases, as hepatic passage normally inactivates serotonin): diarrhoea, flushing, bronchospasm, carcinoid heart disease (right-sided valvular lesions from serotonin)
• On CT: hyperenhancing (vs. adenocarcinoma which is moderately enhancing); desmoplastic mesenteric reaction
• IHC: serotonin-positive; chromogranin A strongly positive; CDX-2 positive

6.4 Small Cell Lung Cancer (SC-NEC)

• Poorly differentiated, G3 NEC; highly aggressive
• Nuclear molding, crush artefact, 60 mitoses/2 mm² on average
• IHC: synaptophysin+, chromogranin A+, CD56+ (>90%), INSM1+, Ki-67 80-100%
• TTF-1 positive in ~80%; CK (dot-like pattern)
• Molecular: TP53 and RB1 co-mutation; almost no MEN1/DAXX/ATRX mutations

7. Prognostic Factors in NETs

7.1 Most Important Prognostic Factors

1. Histologic grade (Ki-67 and mitotic index) - the single most powerful determinant
   • G1 pNETs: 5-year survival 75-90%
   • G2 pNETs: 5-year survival 62-63%
   • G3 NET/NEC: 5-year survival 7-12%
2. Differentiation - well-differentiated (NET) vs poorly differentiated (NEC) - independent of grade
3. Stage (AJCC 8th edition):
   • Local small bowel NET: 5-year cancer-specific survival ~95%
   • Nodal disease: 84%
   • Distant (liver) metastases: 51%; overall survival 32% with distant disease
4. DAXX/ATRX mutational status / ALT phenotype - in pNETs: ALT-positive tumours have ~45% 5-year survival vs ~86% in ALT-negative tumours; routine molecular assessment now recommended
5. Functional status: ~90% of insulinomas are benign; 60-90% of other functioning and nonfunctioning pNETs are malignant
6. Site of origin: pNETs generally more aggressive than midgut NETs of the same grade; rectal NETs tend to be less aggressive
7. SSTR2 expression: 90% of well-differentiated NETs overexpress SSTR2; SSTR2-negative tumours (more common in G3 and insulinomas) cannot benefit from somatostatin analogue therapy or PRRT, and carry a worse prognosis in high-grade tumours
8. Tumour size: > 2 cm strongly associated with malignant behaviour in pNETs; small bowel tumours > 2 cm have high rates of nodal metastasis
9. Lymphovascular and perineural invasion - adverse prognostic feature
10. MEN1 context: pNETs in MEN1 tend to be multiple but often lower grade; however, non-insulinoma pNETs in MEN1 still carry significant malignant potential

• Sabiston Textbook of Surgery, p. 1591; Current Surgical Therapy, p. 1675; Goldman-Cecil Medicine, p. 2795-2803

Summary Table: NET vs NEC

• Goldman-Cecil Medicine (International Edition) - Wolin & Jensen, Chapter 213
• Robbins, Cotran & Kumar Pathologic Basis of Disease (10th ed.), Chapter on Pancreatic NENs
• Sabiston Textbook of Surgery (22nd ed.), Chapter 76
• Yamada's Textbook of Gastroenterology (7th ed.), Chapter 80
• Fischer's Mastery of Surgery (8th ed.)
• Fishman's Pulmonary Diseases and Disorders, Chapter on Lung NENs
• Current Surgical Therapy (14th ed.)
• Henry's Clinical Diagnosis and Management by Laboratory Methods
• Hernandez-Prera et al. (2025) - WHO 5th Edition Endocrine/Neuroendocrine Updates, Arch Pathol Lab Med [PMID: 40335070]